Positive Phase III results for linerixibat in cholestatic pruritus treatment for PBC patients
PBC patients receiving linerixibat saw statistically significant improvement in cholestatic pruritus - or relentless itch.
Themes
Yonalink launches ICTN to position Israel as leader in clinical trial innovation
FDA shares additional draft guidance on CGTs
Barinthus Bio shares ongoing Phase IIb chronic hepatitis B trial results
J&J MedTech wins IDE for Ottava to greenlight trials for surgical robot
Trump 2.0 spells uncertainty for US healthcare, says analyst
Ethics and regulation come into focus in the age of AI-powered clinical trials
Corcept’s relacorilant GRADIENT trial misses primary endpoint
